Velpatasvir (Standard)
Based on 1 Customer Validation
Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 1377049-84-7
- Formula: C49H54N8O8
- Molecular Weight:883.00
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1377049-84-7
-
Appearance Solid
-
Molecular Weight 883.00
-
Formula C49H54N8O8
-
Color White to off-white
-
SMILES
O=C(N([C@H]1C)[C@@H](CC1)C2=NC3=C(C(C=C(OCC4=CC(C5=CN=C([C@H](C[C@H](COC)C6)N6C([C@@H](C7=CC=CC=C7)NC(OC)=O)=O)N5)=CC=C84)C8=C9)=C9C=C3)N2)[C@H](C(C)C)NC(OC)=O
-
Synonyms
GS-5816 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5368-78. [Content Brief]
[2]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]
[3]. Yasmeen S, et al. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats. Environ Sci Pollut Res Int. 2023 Sep;30(42):95660-95672. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz